Lyka Labs Ltd (LYKALABS)

📊 Quarterly Results (₹ Cr)

The financial trajectory shows a clear inflection point: revenue growth is accelerating, with consolidated net total income rising 26.95% YoY in Q1 FY27, up from 37 crores in September 2025 to 42.73 crores in June 2026 on a quarterly basis. However, this growth is not translating into sustainable profitability — EBITDA margin has declined from 13.07% to 11.74% YoY, and quarterly operating performance remains inconsistent, with operating losses in Mar 2026 (-₹9 crores) and Sep 2025 (-₹5 crores). Net profit volatility persists, swinging from ₹2 crores in June 2026 to ₹-8 crores in Mar 2026. The company’s ability to convert sales into operating income remains weak, suggesting scaling challenges. The recent divestment of Lyka BDR International may improve focus but does not resolve underlying margin issues. Without clearer operational leverage or cost discipline, profitability gains may remain episodic.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on margin improvement, export sustainability, or capital allocation strategy in the latest filings. However, the board’s approval of Q1 FY27 results and initiation of subsidiary divestment implies a focus on streamlining operations. The absence of formal guidance on future margins or growth targets suggests caution or uncertainty about near-term profitability trajectory. Investors should monitor subsequent quarters for whether revenue growth stabilizes and whether margin pressures ease through operational refinements.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable capital structure with modest leverage (D/E of 0.52) and consistent equity base of ₹36 crores, but reserves have fluctuated slightly, declining from ₹68 crores in March 2025 to ₹57 crores in March 2026. Borrowings have decreased from ₹39 crores to ₹32 crores over the same period, indicating a slight deleveraging trend. Total assets remain flat at ₹175 crores in March 2026, suggesting limited reinvestment or asset growth. The lack of significant capex or debt-funded expansion implies capital allocation is currently focused on financial discipline rather than aggressive growth. The company appears to be prioritizing balance sheet stability over scaling, possibly in response to margin headwinds.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at approximately 58.16% over the last five quarters, indicating no aggressive dilution or stake sales. FII ownership has modestly increased from 0.17% in Q1FY27 to 0.29%, while DII rose from 0.66% to 0.67%, suggesting gradual institutional accumulation. The number of public shareholders has grown from 26,727 to 29,369, reflecting rising retail interest. No pledging of shares was disclosed in recent filings, and insider buying by promoter Kunal Gandhi and related entities signals confidence in the company’s near-term outlook. The increasing shareholder base may support liquidity but also introduces governance scrutiny.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Persistent margin compression despite revenue growth — consolidated EBITDA margin declined to 11.74% from 13.07% YoY, with no clear corrective action plan disclosed. 2. Volatile profitability — quarterly operating losses in Mar 2026 (-₹9 crores) and Sep 2025 (-₹5 crores) contrast sharply with June 2026 profit of ₹2 crores, indicating lack of earnings stability. 3. Limited international market diversification — 68.03% export growth is concentrated in a few regions, making revenue vulnerable to geopolitical or regulatory shifts. 4. High promoter concentration (58.45%) increases governance and liquidity risks if exit decisions are made.

📋 Recent Filings

• Announcement2026-09-24Lyka Labs Ltd announced that its trading window will close on 1 October 2026 for 48 hours following the release of unaudited Q2 results ending 30 Sept…
• 🔴 Financial Results2026-08-11Lyka Labs Limited announced the voting results from its 47th Annual General Meeting held on 10 August 2026, confirming the passage of all five propose…
• Announcement2026-08-11Lyka Labs Limited issued a revised press release correcting typographical errors in its unaudited Q1 FY27 financial results, which showed revenue grow…
• 🟡 Board Meeting2026-08-10Lyka Labs Limited held its 47th Annual General Meeting on 10 August 2026 via video conference, with 66 shareholders in attendance. Directors Kunal Gan…
• 🟡 Board Meeting2026-08-10Lyka Labs Limited announced the board approved unaudited Q1 FY26 financial results and the divestment of its entire stake in Lyka BDR International Li…
• 🔴 Financial Results2026-08-10Lyka Labs Limited reported Q1 FY27 consolidated net total income of **₹4,272.79 crores**, up 26.95% YoY, driven by 68.03% export revenue growth and 15…
• share transfer2026-07-10Lyka Labs Limited received a SEBI-mandated certificate from MUFG Intime India confirming dematerialized securities for the quarter ended June 30, 2026…
• 🔴 Insider Trading2026-06-26On 26 June 2026, Lyka Labs Limited disclosed insider share purchases by promoter Kunal Gandhi (6,533 shares), his wife Alisha Gandhi (5,000 shares), a…
• Financial Results2026-06-24Lyka Labs Limited has announced that its trading window will close on 1 July 2026 and remain closed until 48 hours after the release of its unaudited …
• Announcement2026-06-17Lyka Labs Limited disclosed a GST audit observation from the Principal Commissioner of CGST & Central Excise, Mumbai East, regarding a demand of Rs. 7…

🧠 Analyst's Read

Lyka Labs is transitioning from a scaling phase to operational consolidation, but margin sustainability and earnings volatility remain key concerns. Investors should watch for margin stabilization in upcoming quarters and clarity on export demand trends, particularly as the company executes its subsidiary divestment and focuses on core operations.

Based on filing content and financial data. Not a recommendation.